Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhengcao Tongfengxiao Capsule is a Traditional Chinese Medicine (TCM) product developed by Guangzhou Lanyun Pharmaceutical Research for the treatment of hyperuricemia. It is specifically formulated to address the TCM syndrome of liver-kidney yin deficiency accompanied by dampness-toxin and blood stasis. The therapeutic approach of the capsule focuses on clearing dampness, resolving toxins, and nourishing the liver and kidney to lower serum uric acid levels. It has been evaluated in a Phase 2 randomized, double-blind, placebo-controlled clinical trial in China (CTR20132115) to assess its efficacy and safety in adult patients with hyperuricemia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zhengcao Tongfengxiao Capsule.